Bin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Bin Xu has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Gong-Li Tang
Key Laboratory of Glyco‐drug Research of Zhejiang Province School of Chemistry and Material Sciences Hangzhou Institute for Advanced Study University of Chinese Academy of Sciences (CAS) Hangzhou China
2 shared publications - Hua Yuan
College of Life Sciences, Shanghai Normal University, Shanghai, China
2 shared publications Chunxi Wang
Chinese Acad Sci, Shanghai Inst Organ Chem, State Key Lab Bioorgan & Nat Prod Chem, Shanghai 200032, Peoples R China
1 shared publication- Chunyang Cao
State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200032, China
1 shared publication Gong-Li Tang
State Key Laboratory of Bio-organic and Natural Products Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, China
1 shared publication- Hai-Xue Pan
State Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry
1 shared publication
Latest Publications
- Open Access
- 3 June 2020
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11, 971
Characterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
Rifamycin derivatives, such as rifampicin, have potent antibiotic activity and have long been used in the clinic as mainstay components for the treatment of tuberculosis, leprosy, and AIDS-associated mycobacterial infections. However, the extensive usage of these antibiotics has resulted in the rapid development of bacterial resistance. The resistance mechanisms mainly include mutations of the rifamycin target RNA polymerase of bacteria and enzymatic modifications of rifamycin antibiotics. One modification is the recently characterized rifamycin degradation catalyzed by Rox enzymes, which belong to the widely occurring flavin monooxygenases. Intriguingly, our recent sequence analysis revealed the rifamycin producers also encode Rox homologs that are not yet characterized. In this work, we expanded the study of the Rox-catalyzed rifamycin degradation. We first showed that the Rox proteins from rifamycin producers have the enzymatic rifamycin SV-degrading activity. Then we used the structurally diverse rifamycin compounds rifampicin and 16-demethylrifamycin W to probe the substrate scope and found that they each have a slightly different substrate scope. Finally, we demonstrated that Rox proteins can also catalyze the transformation of 16-demethylsalinisporamycin to 16-demethylsaliniketal A. Since 16-demethylsalinisporamycin and 16-demethylsaliniketal A are the counterpart analogs of salinisporamycin and saliniketal A, our biochemical findings not only uncover a previously uncharacterized self-resistance mechanism in the rifamycin producers, but also bridge the gap between the biosynthesis of the potential antitumor compound saliniketal A.
- 3 June 2020
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 11, 971
Open AccessCharacterization of the Rifamycin-Degrading Monooxygenase From Rifamycin Producers Implicating Its Involvement in Saliniketal Biosynthesis
Rifamycin derivatives, such as rifampicin, have potent antibiotic activity and have long been used in the clinic as mainstay components for the treatment of tuberculosis, leprosy, and AIDS-associated mycobacterial infections. However, the extensive usage of these antibiotics has resulted in the rapid development of bacterial resistance. The resistance mechanisms mainly include mutations of the rifamycin target RNA polymerase of bacteria and enzymatic modifications of rifamycin antibiotics. One modification is the recently characterized rifamycin degradation catalyzed by Rox enzymes, which belong to the widely occurring flavin monooxygenases. Intriguingly, our recent sequence analysis revealed the rifamycin producers also encode Rox homologs that are not yet characterized. In this work, we expanded the study of the Rox-catalyzed rifamycin degradation. We first showed that the Rox proteins from rifamycin producers have the enzymatic rifamycin SV-degrading activity. Then we used the structurally diverse rifamycin compounds rifampicin and 16-demethylrifamycin W to probe the substrate scope and found that they each have a slightly different substrate scope. Finally, we demonstrated that Rox proteins can also catalyze the transformation of 16-demethylsalinisporamycin to 16-demethylsaliniketal A. Since 16-demethylsalinisporamycin and 16-demethylsaliniketal A are the counterpart analogs of salinisporamycin and saliniketal A, our biochemical findings not only uncover a previously uncharacterized self-resistance mechanism in the rifamycin producers, but also bridge the gap between the biosynthesis of the potential antitumor compound saliniketal A.
- 1 April 2019
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 51 (5) , 539-541
Production of a trioxacarcin analog by introducing a C-3 dehydratase into deoxysugar biosynthesis
- 1 April 2019
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 51 (5) , 539-541
Production of a trioxacarcin analog by introducing a C-3 dehydratase into deoxysugar biosynthesis
- 1 January 2019
- Published by Shanghai Institute of Organic Chemistry in Acta Chimica Sinica
- Vol. 77 (11) , 1089-1098
Recent Advances in the Structural Studies on Cytosine Deaminase APOBEC3 Family Members and Their Nucleic Acid Complexes
- 1 January 2019
- Published by Shanghai Institute of Organic Chemistry in Acta Chimica Sinica
- Vol. 77 (11) , 1089-1098
Recent Advances in the Structural Studies on Cytosine Deaminase APOBEC3 Family Members and Their Nucleic Acid Complexes
- 1 April 2018
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 50 (5) , 516-518
Bioinformatics-guided connection of a biosynthetic gene cluster to the antitumor antibiotic gilvusmycin
Natural products isolated from microbes have served as a prolific source of human, animal, and agricultural drugs. In 1928, Fleming discovered penicillin from Penicillium notatum, which began the microbial drug era. Later, the soil microbiologist Waksman developed a screening process that led to the discovery of streptomycin and other antibiotics from actinomycetes. Such traditional isolation methods have provided most of the antibiotics used today, but frequently lead to high-rediscovery rates of known compounds [1]. With the development of DNA sequencing technologies, the past three decades have witnessed the endeavors of...
- 1 April 2018
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 50 (5) , 516-518
Bioinformatics-guided connection of a biosynthetic gene cluster to the antitumor antibiotic gilvusmycin
Natural products isolated from microbes have served as a prolific source of human, animal, and agricultural drugs. In 1928, Fleming discovered penicillin from Penicillium notatum, which began the microbial drug era. Later, the soil microbiologist Waksman developed a screening process that led to the discovery of streptomycin and other antibiotics from actinomycetes. Such traditional isolation methods have provided most of the antibiotics used today, but frequently lead to high-rediscovery rates of known compounds [1]. With the development of DNA sequencing technologies, the past three decades have witnessed the endeavors of...